Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study

Table 2

Clinical outcomes according to PCI complexity.

	Complex PCI (n = 3651)	Noncomplex PCI (n = 6516)	Unadjusted	value	MV adjusted	value
			HR (95% CI)		HR (95% CI)
MACE^a	280 (7.7%)	290 (4.5%)	1.77 (1.50–2.08)	<0.001	1.63 (1.38–1.92)	<0.001
Death	54 (1.5%)	80 (1.2%)	1.20 (0.85–1.69)	0.307	1.22 (0.85–1.75)	0.275
Cardiac death	33 (0.9%)	39 (0.6%)	1.50 (0.94–2.38)	0.088	1.50 (0.92–2.44)	0.108
MI	109 (3.0%)	87 (1.3%)	2.25 (1.70–3.00)	<0.001	2.16 (1.62–2.87)	<0.001
Target vessel MI	52 (1.4%)	37 (0.6%)	2.51 (1.64–3.82)	<0.001	2.50 (1.59–3.77)	<0.001
Definite or probable ST	44 (1.2%)	27 (0.4%)	2.91 (1.80–4.69)	<0.001	2.71 (1.66–4.41)	<0.001
Any revascularization	400 (11.0%)	487 (7.5%)	1.50 (1.32–1.72)	<0.001	1.38 (1.21–1.58)	<0.001
TVR	234 (6.4%)	249 (2.9%)	1.72 (1.44–2.05)	<0.001	1.56 (1.30–1.87)	<0.001
TLR	182 (5.0%)	190 (2.9%)	1.75 (1.43–2.14)	<0.001	1.59 (1.29–1.95)	<0.001
Stroke	72 (2.0%)	94 (1.4%)	1.35 (0.99–1.83)	0.058	1.36 (1.00–1.86)	0.053
Any bleeding	229 (6.3%)	467 (7.2%)	0.87 (0.74–1.01)	0.074	0.91 (0.77–1.07)	0.245
Clinically relevant bleeding^b	87 (2.4%)	191 (2.9%)	0.80 (0.62–1.03)	0.088	0.86 (0.66–1.11)	0.238

Values are number of events (%) unless otherwise indicated. The following covariates have been included in the Cox regression multivariable model: age, sex, current smoking, body mass index, hypertension, diabetes mellitus, chronic kidney disease, left ventricular ejection fraction, prior MI, prior revascularization (percutaneous coronary intervention and/or coronary artery bypass graft), acute coronary syndrome, mean stent diameter, hemoglobin, platelet count, type of DES implanted, and DAPT duration (as a time-adjusted covariate). BARC = Bleeding Academic Research Consortium; CI = confidence interval; HR = hazard ratio; MACE = major adverse cardiac events; ST = stent thrombosis; TVR = target vessel revascularization; TLR = target lesion revascularization; other abbreviations as in Table 1^a MACE was defined as the composite of cardiac death, myocardial infarction, definite/probable stent thrombosis, or target lesion revascularization. ^b Clinically relevant bleeding was defined as BARC type 2, 3, or 5.